Clinical Report: Triglycerides Linked to Psoriasis Risk
Overview
A Mendelian randomization study found that higher genetically predicted triglyceride levels are associated with an increased risk of psoriasis. The study does not determine the effects of measured triglyceride levels on psoriasis.
Background
Psoriasis is recognized as a systemic immune-mediated condition that may be influenced by lipid metabolism. Understanding the relationship between triglycerides and psoriasis risk is crucial.
Data Highlights
The study included 114,999 samples in the total fatty acid data set, 441,016 samples in the triglyceride data set, and 216,752 samples in the psoriasis outcome data set. The primary analysis reported an odds ratio of 1.17 for genetically predicted triglyceride levels associated with psoriasis.
Key Findings
- Genetically predicted triglyceride levels were associated with psoriasis risk (odds ratio 1.17).
- Supplementary analyses showed significant results for weighted median and weighted mode methods.
- No significant association was found between genetically predicted total fatty acid levels and psoriasis in the primary analysis.
- The study did not include a formal mediation analysis for the fatty acid–triglyceride–psoriasis pathway.
- Heterogeneity was reported among triglyceride-associated variants.
- The study was restricted to European-ancestry data.
Clinical Implications
The findings indicate an association between triglyceride levels and psoriasis risk.
Conclusion
This study identifies a genetic association between triglycerides and psoriasis.
Related Resources & Content
- Medicine, 2023 -- Triglycerides Linked to Psoriasis Risk
- conexiant — GLP-1 Agents May Reduce Psoriasis Severity
- Frontiers in Immunology — Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse
- Frontiers in Medicine — Integrated systems toxicology identifies TCDD-responsive targets linked to immune dysregulation and treatment response in psoriasis
- conexiant — UVB and Psoriasis: More Than Immunosuppression
- GLP-1 Agents May Reduce Psoriasis Severity
- Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse
- Integrated systems toxicology identifies TCDD-responsive targets linked to immune dysregulation and treatment response in psoriasis
- 2026 Guideline on the Management of Dyslipidemia
- Mapping the Causal Landscape of Psoriasis: A Systematic Mendelian Randomization Evidence Synthesis and Development of the MR‐PsO Atlas Platform - Lu - 2026 - Experimental Dermatology - Wiley Online Library
- Cardiovascular Disease and Psoriasis | Dermatology and Therapy | Springer Nature Link
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
